Published Date : Oct 19, 2015
A consensus rating of 1.0 has been allotted to Bio Blast Pharma by brokers, indicating a strong buy rating. The rating was given by the brokers which offer coverage for the company’s stocks. There were two investment analysts that rate the stock with a strong buy suggestion.
A 1-year long consensus cost objective has been allotted by brokerages, amounting to US$28.50 for Bio Blast Pharma. They have also forecasted that the firm will submit a US$0.29 EPS for this quarter. Zacks Investment Research has ranked the pharma firm an industry-wide rank of 84 of 265. The ranking has been based on the ratings allotted to Bio Blast Pharma as well as related companies.
For ORPN, the subject of multiple research reports, with a Buy rating with a US$25.00 price objective over all the shares over Bio Blast Pharma, according to a Sunday. Zacks had upgraded the hold rating previously allotted for Bio Blast Pharma to a buy rating with a US$6.00 target price on the stock, according to an August research report.
Bio Blast Pharma on Thursday opened at 5.26 and the stock achieved a 50-day moving average price of US$5.60. The pharma company also achieved a300 day moving average of US$6.06.
The firm has a 52 week high and a 52 week low of US$8.85 and US$4.50 respectively. The cap for the stock’s market is US$74.85 million.
The most recent earnings posted by Bio Blast Pharma were on Friday, the 21st of August. The biopharma firm had, at the time, reported a US$0.26 earnings for every share. They had successfully overtaken the consensus estimate by Thomson Reuters of US$0.28, by US$0.02